Smartlens, Inc. Secures $5.2 Million Bridge Round to Advance FDA Clearance Process and Prepare for Commercial Launch of miLens

About this update from Lens Technology Co. Ltd. Class A

Round Led by Ambit Health Ventures Positions Smartlens for Market Entry and Future Growth SUNNYVALE, Calif., Oct. 14, 2025 /PRNewswire/ -- Smartlens, Inc., a clinical-stage ophthalmic technology company advancing next-generation glaucoma management devices, today announced the closing of an oversubscribed$5.2 million bridge round led by Ambit Health Ventures. The financing will be used to advance the FDA clearance process and prepare for an expedited market launch following clearance. The round also included continued participation from existing investors Graphene Ventures and Boutique Venture Partners, along with new investment from Harvard Business School Alumni Angels GNY and a group of leading eye care providers. miLens is distinguished as the world's first electronics-free contact lens technology capable of continuous intraocular pressure (IOP) monitoring. Working seamlessly with Smartlens' AI-powered smartphone imaging platform, miLens captures critical pressure fluctuations and enables data-driven treatment optimization. The company plans to initiate commercial activities following FDA clearance, marking a major milestone in transforming glaucoma care worldwide. Advancing Toward Commercial Launch Building on strong clinical progress in its multi-site U.S. pivotal trial, Smartlens has made substantial advancements in regulatory preparation, manufacturing scale-up, and clinical validation. miLens is the world's smallest wearable microfluidic device designed as an electronics-free soft contact lens for continuous, real-world monitoring of intraocular pressure outside of clinical settings. An independent, double-blind survey of 166 ophthalmic practitioners conducted by Market Scope showed exceptionally high interest, with 96.2% expressing intent to adopt the technology once available.miLens offers unprecedented insight for patients with glaucoma, ocular hypertension, and those requiring post-surgical intraocular pressure monitoring. "This financing milestone strengthens our position as we advance through the FDA clearance process and prepare for commercialization," said Savas Komban, CEO and Co-Founder of Smartlens, Inc. "We're laying the foundation for the next generation of glaucoma management—one driven by continuous, data-based insight rather than intermittent snapshots. The continued con...

View stock analysis, news, and events for Lens Technology Co. Ltd. Class A